Tropical Journal of Pharmaceutical Research

Original Research Article | OPEN ACCESS

Effect of sodium zirconium cyclosilicate in combination with insulin and glucose infusion on hyperkalemia treatment

Xuansheng Wu¹, Li Yue², Na Yin³, Feng Dai¹ , Fang He²

¹Department of Renal Endocrinology, Chongqing Yongchuan District Hospital of Traditional Chinese Medicine, Chongqing 402160, China; ²Department of Renal Immunology and Endocrinology, Zhong Xian People's Hospital of Chongqing, China; ³Department of Nephrology, The Southwest Hospital of AMU, Chongqing, China.

For correspondence:- Feng Dai Email: daifeng202301@163.com

Accepted: 7 October 2023 Published: 31 October 2023

Citation: Wu X, Yue L, Yin N, Dai F, He F. Effect of sodium zirconium cyclosilicate in combination with insulin and glucose infusion on hyperkalemia treatment. Trop J Pharm Res 2023; 22(10):2217-2224 doi: 10.4314/tjpr.v22i10.25

© 2023 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..

Abstract

Purpose: To evaluate the efficacy of sodium zirconium cyclosilicate (SZC) in combination with insulin and glucose infusion in managing hyperkalemia.

Methods: A total of 126 patients, who were admitted with hyperkalemia (≥ 5 mmol/L) to the Yongchuan District Hospital of Traditional Chinese Medicine, Chongqing, China from January 2021 to December 2022, were retrospectively studied. Participants were divided into three groups based on different potassium-lowering regimens, viz, SZC group (40 patients), insulin with glucose (IG) group (38 patients) and SZC + IG group (48 patients). Changes in potassium levels, other serum electrolytes (magnesium, sodium, phosphate, calcium), alanine aminotransferase (ALT) and albumin before and after treatment were recorded. Adverse reactions during treatment were also recorded.

Results: Post-treatment, the potassium levels in all three groups exhibited a significant reduction when compared to pre-treatment values (p < 0.05). The SZC + IG group showed the highest efficacy, with a significant reduction in blood potassium levels observed 4 h after administration, which was more pronounced compared to other groups. The SZC + IG group, maintained potassium ion concentration at a normal level for a longer duration and no serious adverse reactions were observed during treatment.

Conclusion: Intervention with SZC + IG lowers blood potassium levels, maintains it within normal range, and is more effective than the individual use of SZC or IG. A combination of sodium zirconium cyclosilicate, insulin and glucose infusion for treating hyperkalemia will need to be investigated further in a large-scale multicenter study.

Keywords: Hyperkalemia, Insulin and glucose infusion, Serum potassium, Sodium zirconium cyclosilicate